

Ace Therapeutics Accelerates Preclinical GI and Hepatology Research with Disease Model Customization Services

Ace Therapeutics recently unveiled disease model customization services to accelerate further the preclinical research on gastroenterology (GI) and hepatology.

NEW YORK, NY, UNITED STATES, July 24, 2024 /EINPresswire.com/ -- Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. Following with the announcement of developing [small molecule drug for glaucoma](#), Ace Therapeutics recently unveiled disease model customization services to accelerate further the preclinical research on gastroenterology (GI) and hepatology.

Gastrointestinal (GI) and liver diseases are complex conditions that can greatly impact a person's quality of life. Research in this field aims to understand the underlying causes of these diseases better, identify potential treatments, and ultimately improve patient outcomes. With a focus on providing cutting-edge solutions for studying diseases of the gastrointestinal tract and liver, Ace Therapeutics' [custom gastroenterology and hepatology models](#) offer researchers the tools and resources needed to accurately reflect the complexities of these diseases and accelerate drug discovery and development in these critical areas.

Key features of Ace Therapeutics' disease model customization services include the ability to customize esophageal disease models, gastrointestinal disease models, liver disease models, pancreatic disease models, and more. Additionally, researchers can benefit from comprehensive data analysis and validation services to ensure the reliability and reproducibility of study results. By leveraging advanced technologies and expertise in these areas, Ace Therapeutics aims to provide researchers with a deeper understanding of disease mechanisms and facilitate the development of novel therapeutics.

As a company dedicated to advancing research in many diseases, Ace Therapeutics recognizes the significance of personalized disease models in the novel therapy development field. Whether clients require organoids, genetically engineered animal models, or advanced microfluidic systems, Ace Therapeutics has the capabilities to support them.

From established up to now, Ace Therapeutics has collaborated with leading pharmaceutical companies and research institutions to advance their research goals and bring cutting-edge

therapies to patients in need. Together, Ace Therapeutics and its partners are committed to revolutionizing the field of life science research for the benefit of patients worldwide.

About Ace Therapeutics

With a team of experienced researchers and state-of-the-art facilities, Ace Therapeutics strives to accelerate the development of innovative therapies that address unmet medical needs. From early-stage research to translational medicine, Ace Therapeutics offers tailored solutions to facilitate preclinical studies, enabling the transformation of promising concepts into life-changing treatments.

Daisy Mostert
Ace Therapeutics
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/729981653>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.